Karyopharm Therapeutics (KPTI) Revenue (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Revenue came in at $34.1 million in Q4 2025, up 11.58% YoY from $30.5 million in Q4 2024, and down 22.63% on a QoQ basis from $44.0 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Revenue (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Revenue data on file, last reported at $34.1 million in Q4 2025.
- Quarterly Revenue rose 11.58% year-over-year to $34.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $146.1 million (up 0.57% YoY) and the FY2025 annual result came in at $146.1 million, up 0.57% from the prior year.
- Revenue retreated to $34.1 million in Q4 2025, from $44.0 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $126.3 million in Q4 2021 to a low of $22.6 million in Q2 2021.
- A 5-year average of $40.2 million and a median of $36.9 million in 2022 frame the typical range for Revenue.
- Annual changes were most pronounced in 2021 — Revenue jumped 259.74% — and 2022, when it plunged 73.41%.
- Tracing KPTI's Revenue over 5 years: stood at $126.3 million in 2021, then sank by 73.41% to $33.6 million in 2022, then climbed by 0.5% to $33.7 million in 2023, then declined by 9.5% to $30.5 million in 2024, then climbed by 11.58% to $34.1 million in 2025.
- The last three Revenue figures came in at $34.1 million (Q4 2025), $44.0 million (Q3 2025), and $37.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Karyopharm Therapeutics | 53.25 Mn | 53.25 Mn | 32.35 Mn | 33.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.43 Mn |
| Dec 31, 2025 | 34.08 Mn |
| Sep 30, 2025 | 44.04 Mn |
| Jun 30, 2025 | 37.93 Mn |
| Mar 31, 2025 | 30.02 Mn |
| Dec 31, 2024 | 30.54 Mn |
| Sep 30, 2024 | 38.78 Mn |
| Jun 30, 2024 | 42.79 Mn |
| Mar 31, 2024 | 33.13 Mn |
| Dec 31, 2023 | 33.75 Mn |
| Sep 30, 2023 | 36.01 Mn |
| Jun 30, 2023 | 37.58 Mn |
| Mar 31, 2023 | 38.70 Mn |
| Dec 31, 2022 | 33.58 Mn |
| Sep 30, 2022 | 36.15 Mn |
| Jun 30, 2022 | 39.68 Mn |
| Mar 31, 2022 | 47.67 Mn |
| Dec 31, 2021 | 126.27 Mn |
| Sep 30, 2021 | 37.69 Mn |
| Jun 30, 2021 | 22.60 Mn |